Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
VSY Biotechnology Attends the 35th APACRS Congress
VSY Biotechnology participated in the 35th APACRS Congress held at the Suntec Singapore Convention & Exhibition Centre in Singapore from June 8-10, 2023. The company showcased its latest product, the AcrivaUD Trinova Pro C Pupil Adaptive® with Sinusoidal Vision Technology…
Harrow Secures US and Canadian Rights to Vevye
Harrow has recently announced a significant development by entering the prescription dry eye disease treatment market. The company has successfully struck a deal to acquire the commercial rights for Vevye (cyclosporine ophthalmic solution 0.1%) in both the United States and…
2023 Recap: Top 15 Firsts in Ophthalmology
In a year marked by groundbreaking achievements, the field of ophthalmology witnessed a series of historic firsts, pushing the boundaries of innovation and patient care. Here are the noteworthy milestones: Pioneering the integration of technology into glaucoma management, the world’s…
Aviceda’s IND Cleared by FDA for GA to AMD Treatment
Aviceda Therapeutics announced that the FDA has granted clearance for the IND for AVD-104. This clearance will allow the company to proceed with the initiation of Phase 2 clinical trials of its leading intravitreal ocular asset for the treatment of…
Top 5 Milestones in Ophthalmology History
In this article, we explore five significant milestones in the history of ophthalmology that have shaped the way we approach eye health and treatment. The ancient Egyptians, known for their advanced civilization and remarkable contributions to various fields, including medicine,…
FDA Calls for Study on Aldeyra’s Reproxalap in DED
Aldeyra Therapeutics announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for reproxalap, an investigational drug candidate designed for the treatment of dry eye disease.…
Reviving Hope for Amblyopia: Late-Stage Treatment
In children with amblyopia, often referred to as “lazy eye,” one eye exhibits weaker vision than the other due to various factors. This weaker eye may struggle with focusing, misalignment due to strabismus, or vision obstruction from conditions like cataracts…
New Experimental Drug Shows Promise in Treating DME
A recent study published in Nature Medicine has unveiled promising insights into a potential breakthrough in the treatment of Diabetic Macular Edema (DME). The study suggests that an experimental drug, part of a new class of therapeutics called “senolytics,” could…
Treatment of Intraocular Melanoma | OBN
Melanoma of the uveal tract (iris, ciliary body, and choroid), though rare, is the most common primary intraocular malignancy in adults. The mean age-adjusted incidence of uveal melanoma in the United States is approximately 4.3 new cases per million people,…
4DMT Reports Positive Interim Data for Wet AMD Treatment
4D Molecular Therapeutics (4DMT) announced positive interim data from the Phase 2 PRISM clinical trial, marking a significant stride in the treatment of wet age-related macular degeneration (wet AMD). Arshad M. Khanani, MD, MA, FASRS, presented the data at the…